Citigroup Inc. Sells 338,596 Shares of Biohaven Ltd. (NYSE:BHVN)

Citigroup Inc. reduced its holdings in Biohaven Ltd. (NYSE:BHVN – Get Rating) by 67.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 162,477 shares of the company’s stock after selling 338,596 shares during the quarter. Citigroup Inc. owned about 0.24% of Biohaven worth $2,255,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. US Bancorp DE raised its stake in shares of Biohaven by 19.1% in the first quarter. US Bancorp DE now owns 586 shares of the company’s stock worth $70,000 after purchasing an additional 94 shares during the last quarter. Cetera Advisor Networks LLC purchased a new stake in shares of Biohaven during the first quarter worth about $332,000. AlphaCrest Capital Management LLC purchased a new stake in shares of Biohaven during the first quarter worth about $344,000. BlackRock Inc. grew its holdings in Biohaven by 0.5% during the 1st quarter. BlackRock Inc. now owns 4,656,866 shares of the company’s stock valued at $552,163,000 after buying an additional 21,586 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Biohaven by 55.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 82,599 shares of the company’s stock valued at $9,794,000 after buying an additional 29,413 shares in the last quarter. 98.01% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald raised their price objective on Biohaven from $27.00 to $31.00 and gave the company an “overweight” rating in a research note on Tuesday, April 4th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Biohaven has an average rating of “Moderate Buy” and an average price target of $38.39.

Biohaven Price Performance

NYSE:BHVN opened at $15.78 on Thursday. The firm has a market capitalization of $1.08 billion, a PE ratio of -1.28 and a beta of 1.04. The business’s fifty day moving average price is $13.85 and its 200 day moving average price is $15.13. Biohaven Ltd. has a 12 month low of $5.54 and a 12 month high of $20.57.

Biohaven Profile

(Get Rating)

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an irreversible myeloperoxidase enzyme inhibitor for the treatment of neurodegenerative diseases.